Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
NYSEAMERICAN:OSTX

OS Therapies 8/14/2024 Earnings Report

OS Therapies logo
$1.76 +0.03 (+1.73%)
Closing price 04:10 PM Eastern
Extended Trading
$1.77 +0.01 (+0.62%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OS Therapies EPS Results

Actual EPS
-$0.26
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OS Therapies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OS Therapies Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

OS Therapies Earnings Headlines

OS Therapies Delays Quarterly SEC Filing
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
See More OS Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OS Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OS Therapies and other key companies, straight to your email.

About OS Therapies

OS Therapies (NYSEAMERICAN:OSTX), a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

View OS Therapies Profile